Red Light Therapy for Pattern Hair Loss (Androgenetic Alopecia): Scientific Evidence

A 2024 clinical trial in Brazil assessed the effect of photobiomodulation on quality of life in 85 men and women with pattern hair loss. Participants received 24 sessions, twice weekly for 20 minutes each at 635 to 675 nm, and completed a quality-of-life questionnaire before and after treatment. Both men and women reported significant improvement in quality of life after treatment, with women showing larger reductions in emotional and psychosocial burden than men, though the study measured quality of life rather than hair regrowth directly.

Comparing patients with and without pattern hair loss who developed hair shedding after long COVID, a 2024 observational study, retrospective, in Poland tested red LED therapy for post-COVID hair loss in 140 patients divided into 4 groups. The LED device delivered 625 to 635 nm red light for about 9.65 minutes per session, 10 times a week, over 10 weeks, at an irradiance of 68 mW/cm² and a dose of 37 J/cm². Hair loss stopped, and results on a simple test of how easily hairs come out turned negative more often in the LED-treated groups, including the group with both telogen effluvium and pattern hair loss, than in those without LED therapy. The therapy was described as safe and well tolerated, though its primary focus was telogen effluvium rather than pattern hair loss on its own.

Researchers in China tested whether pretreating a patient's own concentrated growth factor with a 640 nm laser, before injecting it into the scalp, could improve treatment for pattern hair loss, in a 2024 clinical trial of 10 patients aged 18 to 60 (8 men, 2 women). Each patient received the growth factor injections in both sides of the scalp, with only 1 side pretreated by the 640 nm laser at a dose of 4 J/cm² and the other side left untreated for comparison. The laser-pretreated side produced a greater number of new hairs and fewer malnourished hairs than the untreated side, and no serious adverse events were reported.

Chinese women with pattern hair loss took part in a 2024 randomized controlled trial, single-blind, assigned to topical 2% minoxidil alone or combined with a 655 nm low-level laser helmet. The combination group used the helmet for 20 minutes every other day, alongside twice-daily minoxidil, over 24 weeks, with hair parameters assessed at the middle of the scalp and the crown of the head. The combination produced a significantly greater increase in mean hair diameter than minoxidil alone, though it showed a smaller gain in intermediate hair percentage at the middle of the scalp. Reported side effects across the trial included mild hair shedding, flaking, itching, oiliness, and excess hair growth.

Published in 2024, a review assessed low-level light or laser therapy for male and female pattern hair loss. Researchers screened 298 articles, narrowed the field to 36 focused specifically on this therapy, and ultimately analyzed 7 randomized controlled trials, which used red light from about 620 to 678 nm, including 630, 635, 650, 655, and 660 nm, at irradiances from about 2.34 to 182.8 mW/cm², in sessions of 8 to 36 minutes given 3 to 7 times per week over a therapy duration of about 149 days. The authors concluded that every analyzed trial reported a positive effect on hair loss from this therapy, with no side effects noted.

According to a 2023 review of current treatment guidance, low-level laser therapy remains 1 of several options for pattern hair loss, alongside newer drugs and procedures, drawing on 5,152 participants pooled from the literature discussed. The light therapy devices used red light at 650 and 655 nm, applied to the scalp in sessions of 8 to 20 minutes, 3 to 3.5 times a week. The review concluded that managing pattern hair loss should be a patient-centered process, weighing goals, cost, and comorbidities alongside the efficacy of each available treatment, including light therapy.

A 2023 clinical trial in Italy tested a newer 675 nm laser, less studied than earlier wavelengths, for pattern hair loss in 17 men and women. Participants received 10 sessions of 20 minutes each over about 5 weeks, without any other systemic or topical treatment during the study. Hair shaft density increased significantly by the end of treatment, alongside a reduction in yellow dots and visible blood vessels on the scalp, and the authors reported that the process shrinking follicles into thinner, shorter hairs slowed by about 60%, with no side effects.

Delivering 660 and 808 nm light at a dose of about 40.1 J/cm² alongside pulsed electromagnetic field therapy, a 2023 randomized controlled trial, double-blind and sham-controlled, in Korea treated 80 adults with pattern hair loss over 24 weeks. Sessions ran 15 minutes for the light therapy paired with 10 minutes of pulsed electromagnetic field therapy, given weekly for the first 12 weeks and every other week after that. The combination was found to be a valid and safe treatment option for pattern hair loss, the study concluded, though the source data available did not specify the exact change in hair density.

10 patients (aged 23 to 68, including 6 men and 4 women) with hair loss after a COVID-19 infection, some of whom also met standard severity criteria for pattern hair loss, took part in a small 2022 clinical trial in Italy combining micro-needling, LED light therapy, and growth factors. The LED component used violet and red light at 423 and 640 nm, delivered across the front, sides, crown, and back of the scalp over 20 weeks. The combined protocol appeared to support hair regrowth in this COVID-related hair loss population, though the study's primary focus on COVID-19-triggered sudden hair shedding, rather than classic pattern hair loss, limits how directly the results apply here.

Focusing specifically on the pattern hair loss arms of a broader meta-analysis, a 2022 study found that both red light and infrared light photobiomodulation improved pattern hair loss, drawing on a sample of 966 patients pooled across 36 studies that also examined light therapy for alopecia areata, a separate hair-loss condition. The pattern hair loss analyses covered red light from about 620 to 780 nm and infrared light from about 780 to 1400 nm. Both wavebands were superior to control for pattern hair loss, and the authors concluded that red and infrared photobiomodulation were each effective for treating this condition, distinct from their separately analyzed effect on alopecia areata.

A 2022 observational study analyzed 1,383 patients with pattern hair loss who used an FDA-cleared, 650 nm low-level laser helmet in China. Patients used the device in 20-minute sessions, with mild cases averaging about 38 weeks of use and moderate-to-severe cases about 40 weeks. Male sex, longer or more frequent use, and a history of scalp dandruff were each associated with a better efficacy assessment, the study reported, with more than 80% of users falling between the ages of 18 and 40.

According to a 2022 systematic review and network meta-analysis, low-level laser therapy ranked among the more effective non-surgical treatments for pattern hair loss in both men and women. The analysis drew on 30 randomized controlled trials in men and 10 in women, with light therapy studies using red to near-infrared light at 665 and 808 nm over 24 weeks. For male pattern hair loss, low-level laser therapy ranked just behind platelet-rich plasma and ahead of dutasteride, finasteride, and minoxidil, while for pattern hair loss it ranked above both minoxidil concentrations, though the authors judged the evidence quality behind these top-ranked therapies to be low.

Analyzing 15 studies on low-level laser therapy, a 2021 review from India assessed the treatment's role in pattern hair loss across 527 participants. The devices covered used light from about 600 to 1200 nm, mostly red and near-infrared, applied to the scalp 3 times a week over roughly 4 to 26 weeks. More than half of the reviewed studies showed improvement in hair count, density, or tensile strength, with more recent, better-designed trials showing stronger and more consistent results than earlier, smaller ones, and the review noted low-level laser therapy may also help as an adjunct to hair transplant surgery.

Pooling 646 participants across 7 double-blinded randomized trials, a 2021 systematic review and meta-analysis assessed FDA-approved, home-use low-level light and laser devices for pattern hair loss. Of the 32 home-use devices approved by the FDA as of January 2020, the reviewed trials used red light from about 620 to 678 nm, applied to the scalp in sessions of 8 to 30 minutes, 3 to 7 times a week, over roughly 26 weeks. The meta-analysis found a significant increase in hair density with these devices compared with sham groups, in both comb- and helmet-type designs and in men and women alike. At the end of the study, the authors called for longer-term follow-up and head-to-head comparisons between devices.

Patients with pattern hair loss, its early thinning stage, or sudden shedding after a bodily shock responded to a combined protocol called Trichobiolight in a 2021 clinical trial of about 107 people in Italy. The protocol paired scalp mesotherapy with LED light treatment at 630 nm, delivered in 15-minute sessions 4 to 6 times a week, with the exact schedule tailored to each diagnosis, over a follow-up period that in some patients extended past 3 years. The combined protocol appeared effective for hair regrowth, though 2 of the patients did not complete treatment due to pain and localized inflammation after early sessions.

A 2020 observational study from Spain compiled findings from 10 other published studies on low-level laser therapy for pattern hair loss, conducted in Taiwan, Thailand, the United States, Iran, and Canada between 2017 and 2019. Across these studies, devices used red to near-infrared light from about 630 to 808 nm, with treatment schedules ranging from 3 sessions a week to daily use over periods of 17 weeks to 24 months. The author concluded that low-level laser therapy appeared to be an effective, well-tolerated treatment for pattern hair loss with a good safety profile and few adverse effects, particularly when combined with minoxidil or finasteride. However, the small number of human studies and their generally small sample sizes were not yet sufficient to support general treatment recommendations, and many of the reviewed studies were sponsored by device manufacturers.

In a 2021 review of published literature on low-level light therapy, researchers in Guangzhou, China, set out to explain the biological mechanisms behind its effect on pattern hair loss. The devices discussed in the review used red to near-infrared light spanning roughly 630 to 980 nm, applied to the scalp 2 to 3 times a week over 16 to 26 weeks, at an irradiance of about 649 mW/cm² and doses of 2.5 to 10 J/cm². The review concluded that low-level light therapy appeared to promote hair growth through several proposed cellular pathways, including effects on mitochondrial activity and inflammation, though the exact mechanism remains uncertain.

After 6 months of treatment, a 2021 randomized controlled trial in China compared low-level light therapy, topical minoxidil 5%, and a combination of both for pattern hair loss in 83 women who completed the study. The light therapy group used an iHelmet device with 650 nm laser diodes for 30 minutes per session. Hair density and hair diameter improved significantly in all 3 groups by 6 months, with scalp oil secretion also changing over the course of treatment, according to the study.

Limited to studies using 600 to 1,100 nm wavelengths and at least 16 weeks of treatment, a 2020 review examined low-level laser therapy for pattern hair loss. The review drew on 817 participants across 10 randomized controlled trials, with sessions running 15 to 30 minutes, 3 to 7 times a week, over treatment courses extending up to 26 weeks. All of the sham-controlled trials in the review showed a statistically significant increase in hair diameter or density, and the review described these laser devices as having good safety profiles with only minor adverse effects. The review separately cautioned that some of the included studies had industry ties, a limitation worth weighing against the results.

Across 172 participants pooled by a systematic review of randomized trials, a 2020 meta-analysis examined which device and usage factors most affect how well light therapy works for pattern hair loss. The reviewed devices spanned a wide range of red to near-infrared wavelengths, roughly 520 to 830 nm, applied in sessions of 8 to 30 minutes at irradiances from about 2 to 922 mW/cm² and doses of 4 to 67 J/cm². Using linear regression analysis, the review found that higher per-session energy fluence was associated with a greater increase in hair density, pointing to dose as 1 of the key factors influencing how well low-level laser therapy works.

Aged 19 to 65, 60 participants with pattern hair loss enrolled in a 2020 randomized controlled trial, double-blind and sham-controlled, in Korea testing a helmet-type low-level light therapy device. The device delivered 655 nm red light at a mean output of 2.36 mW/cm² to the scalp over 16 weeks. Hair density increased by about 42 hairs per square centimeter and hair thickness by 7.5 µm in the treated group, compared with a slight decline in the sham group, and no adverse events or side effects occurred.

23 patients with pattern hair loss, 13 men and 10 women, took part in a 2020 clinical trial in Rome, randomized, blinded, and retrospective, combining micro-needling, low-level laser therapy, and platelet-rich plasma. The light therapy used violet and red wavelengths at 423 and 640 nm, delivered to the front, sides, crown, and back of the scalp over 24 weeks, alongside the other 2 treatments. Hair density increased by about 81 hairs per square centimeter over the follow-up period, and the authors concluded that the combined approach was effective for hair regrowth.

Spanning red to near-infrared wavelengths from about 600 to 900 nm, the devices reviewed in a 2019 meta-analysis were tested for pattern hair loss across 667 participants pooled from 8 studies comprising 11 double-blinded randomized controlled trials. Sessions ran 8 to 15 minutes, 3 to 6 times a week, over roughly 16 to 20 weeks, at power outputs of 35 to 530 mW. Hair density increased significantly more with low-level laser therapy than with sham devices across the pooled trials, the researchers reported.

Over 24 weeks, double-blind and sham-controlled, a 2019 randomized controlled trial in Thailand tested a new home-use helmet device for pattern hair loss in 36 men and women. The RAMACAP device delivered red light from about 630 to 670 nm to the scalp at near contact, in sessions of roughly 19 to 20 minutes, 3 times a week, at an irradiance of 3.5 mW/cm² and a dose of 4 J/cm². Hair density, hair diameter, and adverse events were tracked throughout the trial, and the device was reported to be an effective treatment for pattern hair loss in this Thai population.

50 patients aged 17 to 45 with pattern hair loss took part in a 2018 randomized controlled trial testing low-level light therapy added to topical minoxidil 5%. The case group received the light therapy, at 785 nm for 20 minutes, 2 to 3 times a week over 24 weeks, alongside minoxidil, while the control group received minoxidil with a deactivated device. Adding light therapy appeared to improve both recovery rates and patient satisfaction compared with minoxidil alone, with higher mean hair density and diameter in the combined-treatment group.

Comparing treated and sham-treated sides of the same scalp, a 2018 randomized controlled trial, double-blind, in Taiwan tested low-level light therapy for pattern hair loss in 100 adults. The device delivered 650 and 660 nm red light for 30 minutes, 3 times a week, over 24 weeks, at an irradiance of 22 mW/cm². The treated side achieved significantly greater hair coverage than the sham-treated side, at 14.2% versus 11.8%, along with greater improvement in hair thickness, hair count, and investigator assessment at 12 and 24 weeks, and no serious adverse events were observed.

Pooling data from 15,888 participants across 78 studies, a 2018 network meta-analysis compared 6 non-surgical treatments for pattern hair loss, including low-level laser therapy alongside minoxidil, finasteride, dutasteride, and platelet-rich plasma. The light therapy studies included in the analysis used red to near-infrared light from about 620 to 780 nm applied to the scalp. Low-level laser therapy ranked among the more effective options relative to the other non-surgical treatments compared, though the authors noted more research is needed to confirm the relative rankings.

This 2018 meta-analysis systematically reviewed double-blinded, randomized controlled trials for pattern hair loss identified through Medline, Embase, the Cochrane database, and clinicaltrials.org. The included trials used red to near-infrared light from about 470 to 830 nm, applied to the scalp in sessions of 8 to 25 minutes, 3 to 7 times a week, over roughly 16 to 26 weeks, at doses in the range of 48 to 101 J/cm². The meta-analysis appeared to support low-level laser therapy as an effective treatment for pattern hair loss, based on the trials that met its quality criteria.

Focusing on 13 clinical trials, a 2018 review assessed low-level laser therapy for pattern hair loss, drawing on 867 participants. The trials examined light sources spanning roughly 500 to 1100 nm, mostly red and near-infrared devices, applied to the scalp in sessions of 5 to 30 minutes, 3 times a week. 10 of 11 trials that met the review's criteria demonstrated significant improvement in pattern hair loss compared with baseline or controls, though in the remaining study improvement in hair counts and hair diameter did not reach statistical significance.

Covering treatment courses of roughly 16 to 26 weeks, a 2018 review, framed as a clinician's guide, assessed FDA-cleared, home-use photobiomodulation devices for pattern hair loss, drawing on findings across 979 participants. The devices covered emitted red light from about 645 to 665 nm, applied to the scalp in sessions of 90 seconds to 30 minutes, 2 to 4 times a week. The guide was intended to help dermatologists advise patients on device selection, safety, and realistic treatment goals, and it described the reviewed evidence as generally supportive of these devices for hair regrowth.

In Iran, a 2017 randomized controlled trial compared 2 low-level laser devices for pattern hair loss in 90 adults aged 18 to 70: a 655 nm laser hat, a combined 655 and 808 nm laser scanner, and an untreated control group. Each active group received red or red-plus-infrared light 3 times a week for 16 weeks, at doses of 1 to 3 J/cm². The authors concluded that the laser scanner produced a significantly greater increase in hair density than either the laser hat or the control group, with no observable adverse effects from either device.

45 women with pattern hair loss took part in a 2017 randomized controlled trial comparing topical minoxidil, low-level light therapy, and a combination of both. The light therapy group used the iGrow helmet-type LLLT device at 655 nm for 25 minutes, 3 times a week, over 4 months, while the combination group added the same regimen to twice-daily topical minoxidil 5%. Regrowing hair follicles increased significantly by 4 months across all 3 groups, with the combination group showing the best results on clinical scoring and patient satisfaction, the researchers reported.

Among healthy women aged 18 to 60, a 2017 randomized controlled trial tested a wearable, cap-style laser device for pattern hair loss. The HANDI-DOME LASER delivered 650 nm red light to the scalp every other day for 17 weeks, at an irradiance of about 2.34 mW/cm² and a power of 1.36 W. The device was described as a safe and effective treatment for pattern hair loss in this group of women.

A 2017 review pooled data from 680 participants across 11 studies of low-level laser therapy for pattern hair loss. The devices reviewed used red and near-infrared light from 600 to 780 nm, applied to the scalp 2 to 3 times a week over periods of 56 to 730 days, at irradiances up to about 92 mW/cm². 9 of 11 studies assessing hair count or density found statistically significant improvement, though hair thickness and tensile strength improved in only 2 of 4 studies that measured them, and patient satisfaction was positive but less pronounced than the objective results.

In an office-based clinic in Rio de Janeiro, Brazil, a 2014 observational study looked at low-level laser therapy for pattern hair loss in 32 men and women, used either on its own or alongside minoxidil or finasteride. Patients were treated with a 655 nm laser comb for 8 to 15 minutes, 3 times a week, over a period that in some cases extended to 24 months. Researchers found that 28 of the 32 patients showed at least moderate improvement, whether treated with the laser comb alone or in combination with medication, with benefits appearing as early as 3 months and no adverse reactions reported.

Researchers in Rochester, New York, tested a combination laser and LED device for pattern hair loss in a randomized controlled trial, double-blind and sham-controlled, of 42 women aged 18 to 60. The TOPHAT655 device delivered 655 nm red light to the scalp for 25 minutes every other day over 16 weeks, at a dose of 67 J/cm² per session. Hair counts appeared to increase substantially more with the active device than with the sham, a difference of about 37% over the study period, and no adverse events or side effects were reported.

This 2014 multicenter randomized controlled trial, sham-device-controlled, tested a low-level laser comb device for pattern hair loss in 225 men and women with pattern hair loss. Participants applied the comb device, which emitted red light at about 622 to 688 nm, to the whole scalp 3 times a week for 26 weeks, at irradiances of about 3 to 90 mW/cm² and doses of 1 to 4 J/cm². The authors concluded that terminal hair density increased significantly more with the laser comb than with a sham device, with no serious adverse events reported.

In 2013, a randomized controlled trial in Korea tested a home-use, helmet-type low-level light therapy device for pattern hair loss in 40 adults. Participants wore the device, which emitted red light at 630, 650, and 660 nm, for 18 minutes daily over 24 weeks, at irradiances of about 61 to 183 mW/cm² and a dose of 47.9 J/cm². The trial found that hair density and mean hair diameter improved significantly more with the device than with a sham device, though only the investigator's assessment of hair regrowth showed a significant difference, not the participant's own assessment. No serious adverse reactions were detected.

Surveying recent medical and procedural advances, a brief 2023 review touched on photobiomodulation as 1 of several emerging options for pattern hair loss, alongside low-dose oral minoxidil, spironolactone, and newer hair transplant techniques. The light therapy discussed used red light from about 620 to 678 nm, applied to the scalp for 30 minutes, 3 to 4 times a week. The review offered only a brief, partially detailed look at where these treatments stand, without providing extensive outcome data specific to light therapy for pattern hair loss.

Comparing combination therapy against minoxidil alone, a 2023 review of 5 randomized controlled trials assessed low-level light therapy paired with topical minoxidil for pattern hair loss. The trials used light from 600 to 1100 nm, applied for at least 16 weeks, alongside 2% or 5% topical minoxidil. Results across the 5 trials were mixed, with some showing the combination produced greater hair density than minoxidil alone, 1 showing equivalent regrowth between combination and higher-dose minoxidil, and another finding no statistical difference, with the studies that did show an advantage for combination therapy noting it tended to fade by the end of the study period.

Emerging and established therapies for pattern hair loss were surveyed in a 2022 review drawing on 5,376 participants across the literature discussed. Among the light-based options, low-level laser therapy spanning roughly 500 to 1100 nm, alongside 1550 nm fractional lasers, was reviewed alongside finasteride, minoxidil, microneedling, platelet-rich plasma, and several experimental cellular and molecular therapies. The review found responses to these treatments remained inconsistent, particularly in women, and concluded that combination therapy is more likely than any single treatment to produce a durable improvement in pattern hair loss.

Surveying the full range of options for pattern hair loss, from topical drugs to light-based devices, a 2021 review weighed efficacy, side effects, cost, and ethics across 8,812 participants pooled from the literature it covered. Among the light-based options, low-level light therapy at 620 to 660 nm, given in 10-minute daily sessions, was 1 of only 3 FDA-approved treatments discussed, alongside topical minoxidil and oral finasteride. The review found these approved therapies to be only part of a much larger, partially effective set of options, and it stressed that treatment choice should weigh each patient's needs, compliance, and budget over any potential financial benefit to the practitioner.

In Egypt, a 2021 clinical trial evaluated low-level laser therapy for pattern hair loss and telogen effluvium, a separate hair-shedding condition, in 20 women. The device delivered 655 nm red light to the scalp for 20 minutes per session over 16 weeks. The treatment appeared only partially effective based on the study's photographic and hair-count assessments. The findings also revealed that the source data were too fragmented to specify exact response rates for the pattern hair loss group.

Reviewing 9 original studies on fractional laser devices, researchers in Boston assessed this emerging approach to pattern hair loss in a 2019 review covering 106 participants. The fractional lasers examined used wavelengths of 1060, 1550, 1927, and 2940 nm, spanning near-infrared to far-infrared, delivered in sessions ranging from 3 to 15 times a week. The review found preliminary evidence that fractional laser therapy has a positive effect on hair regrowth, though it cautioned that most of the literature was limited to case reports and small studies. Researchers called for well-designed randomized controlled trials to confirm efficacy and safety.

Of the 9 trials assessed in a review published in 2017, 5 were randomized controlled trials evaluating low-level laser therapy for pattern hair loss, covering comb and helmet or cap devices. The therapies covered used red to near-infrared light spanning roughly 613 to 846 nm, applied to the scalp in sessions of 5 to 20 minutes, 3 times a week, over about 180 days, at a dose of 4 J/cm². The review found that comparing results across trials was difficult given small sample sizes, inconsistent visual evidence, and wide variation in study duration and outcome measures, and it called for standardized protocols and longer, 12-month trials going forward.

Examining low-level light therapy as a treatment for pattern hair loss, a 2014 review looked at devices used for pattern hair loss in men and women. The therapies reviewed used red light at 650 and 655 nm, applied to the scalp in sessions of 5 to 18 minutes, given 2 to 7 times per week, at power outputs of 5 to 205 mW. According to the review, the evidence for these devices was mixed, with some studies showing a significant increase in hair growth and others limited by small samples or potential bias.

A 2012 review examined laser and light therapies for pattern hair loss, alongside spot baldness, drawing on 127 participants pooled from the studies covered. The therapies used a wide range of light sources spanning about 308 to 2940 nm, from ultraviolet through far-infrared, applied to the scalp in sessions given 3 to about 11 times per week over roughly 180 to 360 days, at doses of 80 to 120 J/cm² and a power of 5 mW. The review found these therapies to be only partially effective for hair regrowth in these conditions, and the authors also discussed possible biological mechanisms behind the effect.